A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

F. Cappuzzo, S. Novello, F. De Marinis, G. Selvaggi, G.V. Scagliotti, F. Barbieri, M. Maur, M. Papi, E. Pasquini, S. Bartolini, L. Marini, L. Crinò
  • Lung Cancer, June 2006, Elsevier
  • DOI: 10.1016/j.lungcan.2006.03.004

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/j.lungcan.2006.03.004

The following have contributed to this page: Dr Federico Cappuzzo